While reinforcing the importance of treating all known risk factors that contribute to atherosclerotic cardiovascular disease, ASCVD, physicians also need to recognize and treat systemic inflammation in CV disease, according to Dr. Quigley, who addresses the importance of identifying and reducing residual inflammatory risk.